Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) closed the day trading at $654.04 up 0.17% from the previous closing price of $652.91. In other words, the price has increased by $0.17 from its previous closing price. On the day, 1.12 million shares were traded. REGN stock price reached its highest trading level at $664.0 during the session, while it also had its lowest trading level at $645.0.
Ratios:
For a better understanding of REGN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.13 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.28. For the most recent quarter (mrq), Quick Ratio is recorded 3.33 and its Current Ratio is at 4.06. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Rothschild & Co Redburn on August 14, 2025, initiated with a Buy rating and assigned the stock a target price of $890.
Wells Fargo Downgraded its Overweight to Equal Weight on May 30, 2025, while the target price for the stock was maintained at $580.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 29 ’25 when Christine Poon bought 6,500 shares for $652.91 per share.
McCourt Marion sold 1,000 shares of REGN for $844,610 on Nov 01 ’24. The EVP Commercial now owns 12,931 shares after completing the transaction at $844.61 per share. On Nov 01 ’24, another insider, MARION E MCCOURT, who serves as the Officer of the company, bought 1,000 shares for $844.61 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, REGN now has a Market Capitalization of 68739252224 and an Enterprise Value of 61496860672. As of this moment, Regeneron’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.66, and their Forward P/E ratio for the next fiscal year is 15.28. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.82. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.82 while its Price-to-Book (P/B) ratio in mrq is 2.22. Its current Enterprise Value per Revenue stands at 4.316 whereas that against EBITDA is 14.144.
Stock Price History:
The Beta on a monthly basis for REGN is 0.32, which has changed by -0.22470367 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, REGN has reached a high of $935.86, while it has fallen to a 52-week low of $476.49. The 50-Day Moving Average of the stock is 12.59%, while the 200-Day Moving Average is calculated to be 9.64%.
Shares Statistics:
Over the past 3-months, REGN traded about 1.07M shares per day on average, while over the past 10 days, REGN traded about 1062640 shares per day. A total of 103.50M shares are outstanding, with a floating share count of 102.14M. Insiders hold about 3.61% of the company’s shares, while institutions hold 85.77% stake in the company. Shares short for REGN as of 1760486400 were 2927169 with a Short Ratio of 2.73, compared to 1757894400 on 2985318. Therefore, it implies a Short% of Shares Outstanding of 2927169 and a Short% of Float of 2.92.
Earnings Estimates
The market rating for Regeneron Pharmaceuticals, Inc (REGN) is a result of the insights provided by 19.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $10.26, with high estimates of $11.39 and low estimates of $8.95.
Analysts are recommending an EPS of between $45.85 and $39.78 for the fiscal current year, implying an average EPS of $43.23. EPS for the following year is $36.5, with 9.0 analysts recommending between $44.9 and $29.56.
Revenue Estimates
20 analysts predict $3.74B in revenue for. The current quarter. It ranges from a high estimate of $4.11B to a low estimate of $3.39B. As of. The current estimate, Regeneron Pharmaceuticals, Inc’s year-ago sales were $3.79BFor the next quarter, 20 analysts are estimating revenue of $3.4B. There is a high estimate of $3.78B for the next quarter, whereas the lowest estimate is $3.17B.
A total of 25 analysts have provided revenue estimates for REGN’s current fiscal year. The highest revenue estimate was $14.57B, while the lowest revenue estimate was $13.85B, resulting in an average revenue estimate of $14.19B. In the same quarter a year ago, actual revenue was $14.2BBased on 24 analysts’ estimates, the company’s revenue will be $14.92B in the next fiscal year. The high estimate is $16.27B and the low estimate is $13.33B.
